- Wall Street anticipates Gyre Therapeutics, Inc. (NASDAQ:GYRE) to report earnings per share (EPS) of $0.08 and revenue of around $35.4 million for the upcoming quarter.
- In the previous quarter, GYRE’s revenue outperformed expectations, indicating a positive trend with a year-over-year increase.
- GYRE’s strategic acquisition and advancements in drug development, including Hydronidone and pirfenidone, highlight its growth potential in the biopharmaceutical sector.
Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a biopharmaceutical company focused on developing innovative therapies. The company is preparing to release its quarterly earnings on March 16, 2026. Wall Street anticipates earnings per share (EPS) of $0.08 and revenue of around $35.4 million. GYRE operates in a competitive landscape, with a focus on drug development and strategic acquisitions.
In the previous quarter, GYRE reported earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 by 50%. However, the company achieved revenue of $37.2 million, surpassing expectations by 2.17%. This revenue growth is notable compared to the $27.87 million reported in the same quarter last year. Despite the earnings miss, GYRE’s revenue performance indicates a positive trend.
For the full year 2025, GYRE’s revenue increased by 10%, reaching $116.6 million, aligning with their revised guidance. Looking ahead, the company projects 2026 revenue between $100.5 million and $111 million. GYRE’s strategic acquisition of Cullgen aims to enhance its capabilities in targeted protein degradation, with the deal expected to close in the second quarter of 2026.
GYRE is making significant strides in drug development, particularly with Hydronidone. The company has aligned with China’s Center for Drug Evaluation for conditional approval and priority review. A New Drug Application is expected in the first half of 2026. Additionally, GYRE has completed patient enrollment for a Phase 3 trial of pirfenidone for pneumoconiosis.
Financially, GYRE maintains a strong position with a low debt-to-equity ratio of 0.011, indicating minimal reliance on debt. The current ratio of 6.19 suggests a solid ability to cover short-term liabilities. However, the enterprise value to operating cash flow ratio is high at 172.86, reflecting the company’s valuation compared to its cash flow.
